CTAD 2025 Conference

CTAD 2025 Conference

Dates: November 6-9, 2025 Location: San Diego Convention Center, California, USA Organizer: CTAD (Clinical Trials on Alzheimer's Disease) Website: [ctad-alzheimer.com](https://ctad-alzheimer.com)

Overview

CTAD 2025 was held in San Diego, California, presenting the latest clinical trial results in [Alzheimer's disease](/diseases/alzheimers-disease) research. The conference is the premier venue for presenting Phase 2 and Phase 3 clinical trial data, bringing together academic researchers, pharmaceutical companies, and regulatory agencies["@ctad2025"].

Key Focus Areas

Anti-Amyloid Therapies

CTAD 2025 featured extensive data on anti-amyloid monoclonal antibodies:

CTAD 2025 Conference

Dates: November 6-9, 2025 Location: San Diego Convention Center, California, USA Organizer: CTAD (Clinical Trials on Alzheimer's Disease) Website: [ctad-alzheimer.com](https://ctad-alzheimer.com)

Overview

CTAD 2025 was held in San Diego, California, presenting the latest clinical trial results in [Alzheimer's disease](/diseases/alzheimers-disease) research. The conference is the premier venue for presenting Phase 2 and Phase 3 clinical trial data, bringing together academic researchers, pharmaceutical companies, and regulatory agencies["@ctad2025"].

Key Focus Areas

Anti-Amyloid Therapies

CTAD 2025 featured extensive data on anti-amyloid monoclonal antibodies:

• [Lecanemab](/entities/lecanemab) ([Leqembi](/drugs/leqembi)) — CLARITY-AD long-term follow-up data
• [Donanemab](/entities/donanemab) ([Kisunla](/drugs/kisunla)) — TRAILBLAZER-ALZ 2 extended outcomes
• Anti-amyloid next-generation antibodies — Novel binding profiles and safety data
• Combination approaches — Anti-amyloid with [tau](/proteins/tau) or neuroinflammation targets

Anti-Tau Approaches

Tau-targeted therapies were a major focus:

• Anti-tau antibodies — Multiple Phase 2/3 programs
• Tau aggregation inhibitors — Small molecule programs
• Tau PET imaging correlations with clinical outcomes
• Tau downstream effects — Synaptic function and neuronal loss

Biomarker-Driven Trials

The integration of biomarkers into clinical trials was prominently featured:

• Blood-based biomarkers for patient selection and endpoint assessment
• [p-tau217](/biomarkers/p-tau-217) as a surrogate endpoint
• Amyloid PET standardization and quantification
• Neurodegeneration markers ([NfL](/biomarkers/neurofilament-light-chain-nfl), t-tau)

Prevention Trials

Updates from Alzheimer's prevention initiatives:

• Dominantly Inherited Alzheimer Network (DIAN) trials
• Alzheimer's Prevention Initiative (API) updates
• A4 Study (Anti-Amyloid in Asymptomatic Alzheimer's)
• Risk reduction trials in sporadic AD

Novel Trial Designs

Innovative approaches to clinical trial methodology:

• Platform trials for efficient drug testing
• Adaptive designs in late-stage trials
• Digital endpoints and remote monitoring
• Diversity in clinical trials strategies

Notable Sessions

Late-Breaking Oral Presentations

• Phase 3 trial results from major pharmaceutical companies
• Novel therapeutic agent first-in-human data
• Regulatory pathway discussions

Focused Symposia

• "Lessons Learned from Anti-Amyloid Trials" — Optimizing future studies
• "Tau as a Therapeutic Target" — Current status and future directions
• "Biomarkers as Surrogate Endpoints" — Regulatory perspectives
• "Clinical Outcome Assessment" — Cognitive and functional measures

Workshops

• Statistical Methods for Alzheimer's clinical trials
• Clinical Operations in diverse populations
• Data Sharing and collaborative analyses

Industry Presence

CTAD 2025 featured presentations from leading pharmaceutical and biotechnology companies:

• Eisai/ Biogen — Leqembi development program
• Eli Lilly — Donanemab and other pipeline programs
• Roche/ Genentech — Anti-amyloid and anti-tau programs
• Johnson & Johnson — Neuroscience pipeline
• AbbVie — Neurodegeneration portfolio
• Axon Neuroscience — Tau vaccine program

Venue: San Diego

San Diego Convention Center

Located in downtown San Diego, the convention center provides state-of-the-art facilities for clinical presentations and poster sessions.

San Diego Biotechnology Hub

San Diego is home to a thriving biotechnology community:

• UC San Diego — Leading Alzheimer's research center
• Scripps Research Institute — Drug discovery expertise
• Sanford Burnham Prebys — Neurobiology research
• Multiple biotechnology companies — Alzheimer's drug development

Research Collaboration

San Diego has established itself as a major center for Alzheimer's clinical research:

• Multiple memory clinics and research centers
• Strong academic-industry partnerships
• Diverse patient populations for clinical trials

Related Conferences

• [CTAD 2026](/events/ctad-2026) — Boston, USA
• [AAIC 2025](/events/aaic-2025) — San Diego, USA
• [AD/PD 2025](/events/adpd-2025) — Vienna, Austria

See Also

• [Conference Index](/events/conference-index)
• [CTAD Conference](/events/ctad)
• [Alzheimer's Disease Clinical Trials](/diseases/alzheimers-disease#clinical-trials)
• [Lecanemab](/drugs/leqembi)
• [Donanemab](/drugs/kisunla)

References